Transient Protein Expression Market: Growing Adoption of Precision Medicines COVID-19 Impact and Global Analysis

According to The Insight Partners market research study titled “Transient Protein Expression Market to 2027 – COVID-19 Impact and Global Analysis – by Product Type, Application, and End User,” the global transient protein expression market is expected to reach US$ 983.10 million by 2027 from US$ 660.00 million in 2019. The market is estimated to grow at a CAGR of 5.3% from 2020 to 2027. The report highlights the trends prevalent in the global transient protein expression market and the factors driving the market along with those that act as deterrents to its growth.

Transient protein expression is a procedure that is usually used to obtain a few milligrams of protein to a hundred milligrams of protein. It is a procedure expressed in a short time once the DNA encoding expression has been introduced to animal or plant cells. It is performed using an electroporation technique that allows large numbers of mutants to be screened for their abilities to network productively with receptors and effectors.  

Get sample Research on Transient Protein Expression Market study at: https://www.theinsightpartners.com/sample/TIPRE00017081/

Transient Protein Expression Market Competitive analysis and Landscape

Prominent players operating in transient protein expression market include THERMO FISHER SCIENTIFIC INC.; MERCK KGaA; QIAGEN; GenScript; Promega Corporation; Takara Bio Inc.; MERIDIAN BIOSCIENCE, INC.; New England Biolabs; Agilent Technologies, Inc.; Mirus Bio LLC; and Sino Biological Inc.

The market players are focused toward bringing new and innovative products and services to sustain their position in the market. For instance, in September, 2017, Thermo Fisher Scientific Inc. launched its new PureLink Fast Low-Endotoxin Plasmid Purification Midi and Maxi Kits, which significantly reduce plasmid purification time to accelerate protein expression. Such developments are expected to help the market grow during the forecast period.

Various companies, including biopharmaceuticals and contract research and development organizations have channelized their efforts toward the development of products based on transient protein expression based products. The adoption of transient protein expression allow companies to get various genes to develop recombinant proteins without delaying cell line generation. Thus, the quick process of cell line development with required gene expression, companies are widely attracted towards uniform proteins that have drug-like properties, which allows production of vaccines and viral vectors. In addition, the transient protein expression process is widely being used in the production of monoclonal antibodies, modified human proteins, growth factors and cytokines, hormones, and blood products.

The COVID–19 pandemic has resulted in rise in the use of transient protein expression in vaccine development. Various researchers have started studying the novel coronavirus extensively, with the use of transient protein expression. For instance, in March–April 2020, Absolute Antibody (UK) increased the production of multigram quantities of multiple anti-SARS-CoV-2 spike proteins to develop neutralizing antibodies. Similarly, the transient protein expression was widely used to produce a positive control protein in the development of in-vitro diagnostics kits.

Growing Adoption of Precision Medicines

Technological advancements have increased the adoption of molecular biology techniques for developing various therapeutic or treatment modalities. Different therapeutic modalities utilize genomic, transcriptomic information that facilitates the discovery of biomarkers to monitor diseases and predict their risks. The use of personalized or precision medicines has dramatically risen due to the awareness regarding genetic variations among people. For instance, mRNA-mediated therapy is used for treating several diseases, as the therapy is characterized by decreased immunogenicity, superior translation efficacy, enhanced stability, pharmaceutical safety, and transient protein expression, since only the mRNA is modified without incorporating the host genome.

Similarly, pharmaceutical and biotechnology industries have developed various techniques to treat cancer and neurodegenerative diseases. Transient gene expression technique has led to significant developments in the research related to neurotrauma and neurodegenerative, and resulted in the introduction of precision medicines for these conditions. Technological advancements in epigenetics, genetics, and proteomics are supporting the development of therapeutics for the treatment of various genetic and rare genetic diseases caused by single and multiple cell disorders.

Transient Protein Expression Market: Segmental Overview

Based on product type, the global transient protein expression market is segmented into instruments, reagents, vectors, and competent cells. In 2019, the instruments segment held the largest market share. This segment is also expected to dominate the market in 2027 as they are the reducing human input is which enables continuous cell maintenance and protein production. Moreover, the same segment is anticipated to grow at the fastest rate during the forecast period.

Based on application, the global transient protein expression market is segmented into genomic research, gene therapy, bio production, cancer research, and drug development. In 2019, the genomic research segment held the largest market share in the transient protein expression market. This segment is also expected to dominate the market by 2027 as it increases DNA sequencing performance. Moreover, transient protein expression has helped in the study of all the genes of a person (the genome), including their interactions with each other as well as the environment.

Buy Complete Report of Transient Protein Expression Market study at: https://www.theinsightpartners.com/buy/TIPRE00017081/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876

Back to news